The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms

Somayeh Yazdanparast; Zoufang Huang; Shayan Keramat; Mehrdad Izadirad; Yi-Dong Li; Letao Bo; Ahmad Gharehbaghian; Zhe-Sheng Chen

doi:10.3389/fonc.2022.904637

The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms

Front Oncol. 2022 Jun 2:12:904637. doi: 10.3389/fonc.2022.904637. eCollection 2022.

Authors

Somayeh Yazdanparast¹, Zoufang Huang², Shayan Keramat³, Mehrdad Izadirad¹, Yi-Dong Li⁴, Letao Bo⁴, Ahmad Gharehbaghian¹, Zhe-Sheng Chen⁴

Affiliations

¹ Department of Hematology and Blood Bank, School of Allied Medical Science, Shahid Beheshti University of Medical Science, Tehran, Iran.
² Ganzhou Key Laboratory of Hematology, Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
³ Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
⁴ Department of Pharmaceutical Sciences, St John's University, New York, NY, United States.

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous neoplasm and is characterized as the most common subtype of non-Hodgkin lymphoma (NHL). Despite 60-70% of all patients being cured with R-CHOP therapeutic regimen (Cyclophosphamide, doxorubicin, vincristine, and prednisone, combined with rituximab), remaining patients display aggressive disease. Therefore, there is an urgent need to develop novel diagnostic, prognostic, and predictive biomarkers. Recently, exosomal miRNAs have been approved as novel biomarkers in DLBCL due to their potential involvement in lymphomagenesis.

Material and methods: We conducted an investigation on the potential role of exosomal miRNAs as diagnostic, prognostic, and predictive biomarkers in DLBCL in the PubMed, Scopus, and Web of Science search engines. We searched by using a combination of keywords, such as diffuse large B-cell lymphoma, DLBCL, miRNA, microRNA, miR, exosome, exosomes, exosomal, extracellular vesicles, EVs, and secretome. Then, search results were narrowed based on specific inclusion and exclusion criteria.

Results: Twelve articles were eligible for our systematic reviews. Among them, nine discussed diagnostic biomarkers, three considered prognostic significance, four evaluated therapeutic efficacy, two studies were conducted in vitro, and three assessed molecular pathways associated with these exosomal miRNAs in DLBCL.

Discussion: According to our systematic review, exosomal miRNAs are not only useful for diagnosis and prognosis in DLBCL but are also promising therapeutic tools and predictors of response to therapy. Although promising results so far, more research is required to develop innovative biomarkers.

Keywords: diagnosis; diffuse large B-cell lymphoma (DLBCL); exosome; miRNAs; prognosis; treatment.

Publication types

Systematic Review